Single Agent Chemotherapy Market - By Drug Class , By Cancer , By Route of Administration , By End User and By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2024-2030

Single Agent Chemotherapy Market Overview: 

Single Agent Chemotherapy Market size is estimated to reach $8.2 billion by 2030, growing at a CAGR of 3.9% during the forecast period 2024-2030. The increasing prevalence of cancer globally is a major driver of the market, as the rising number of cancer cases necessitates effective treatment options. Government investment in healthcare infrastructure, advances in drug development and the approval of new single agent chemotherapeutic drugs are further propelling market growth.

Innovations in drug delivery systems, such as targeted delivery mechanisms and nanotechnology, are expected to enhance the precision and effectiveness of chemotherapy treatments. The market is also witnessing a shift towards personalized medicine, where treatment regimens are tailored to the genetic profile of individual patients, thereby improving outcomes and minimizing adverse effects. Furthermore, the integration of artificial intelligence and machine learning in drug discovery and development processes is anticipated to accelerate the creation of new and more effective chemotherapeutic agents.

Market Snapshot: 

Single Agent Chemotherapy Market - Report Coverage:

The “Single Agent Chemotherapy Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Single Agent Chemotherapy Market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

• The focus on the COVID-19 pandemic led to disruptions in healthcare systems, including delayed cancer screenings and a shift in resource allocation. Consequently, the diagnosis and management of cancer, including the single agent chemotherapy was affected. 
• The Russia-Ukraine conflict indirectly impacted the single agent chemotherapy market. The availability of research funding and talent acquisition have been affected slowing down advancements in chemotherapy drugs.

Key Takeaways:

• Dominance of North America

Geographically, North America held the largest share with 35% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030. North America, particularly the United States, faces a significant burden of cancer. An aging population and unhealthy lifestyle choices are contributing factors. The American Cancer Society released its Cancer Statistics 2023 report, which showed that in 2023 in the United States, there will be nearly 2 million new cases of cancer diagnosed. This translates to a larger pool of patients requiring cancer treatment, including single agent chemotherapy. 

• Breast Cancer is the largest Segment

In terms of cancer, breast cancer is the largest segment in 2023 due to its high prevalence and significant mortality rate, making it a primary focus for treatment advancements. The disease affects a large female population globally, with increasing incidence rates driven by factors such as lifestyle changes, genetic predispositions and longer life expectancies. According to the American Cancer Society, breast cancer is the most common cancer diagnosed among women in the United States. It is the 2nd leading cause of death from cancer among women. Single agent chemotherapy is often utilized in breast cancer treatment due to its efficacy in specific stages and types of breast cancer, providing a less complex and targeted approach compared to combination therapies.

• Improved Healthcare Infrastructure to Drive the Market

Government initiatives and investments are improving healthcare infrastructure globally. In July 2024, the Australian government invested approximately $720 million into developing the 150-bed Queensland Cancer Centre which is slated to open in 2028. Its establishment aligns with the government’s Queensland Cancer Plan, a 10-year initiative with over $1.1 billion in investments. In September 2023, the Kerala Infrastructure Investment Fund Board (KIIFB) allotted approximately $24 million towards ensuring the full-fledged operations of Cochin Cancer Research Centre (CCRC). Such developments translate to better access to advanced cancer treatment facilities, including chemotherapy, thereby boosting the single agent chemotherapy market.

• High Cost of Treatment to Impede Growth

Single Agent Chemotherapy drugs can be expensive, posing a significant financial burden on patients. As cancer survival rates rise, so do the price tags of life-saving treatments. Monthly drugs costs may reach $100,000, causing many Americans to struggle with the physical and emotional effects of high out-of-pocket medical costs. Even worse, others are completely priced out of the hope for a cure. $245 billion is expected to be spent on cancer care costs in the U.S. by 2030, as per the American Association for Cancer Research. Nearly 20% of cancer patients and their loved ones surveyed by The Mesothelioma Center at Asbestos.com estimated that they spent more than $20,000 each year in total out-of-pocket costs.

Market: Market Share (%) by Geography, 2023

For more details on this report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Single Agent Chemotherapy Market. The top 10 companies in the Single Agent Chemotherapy Market are:

1. F. Hoffmann-La Roche AG
2. Bristol Myers Squibb
3. AbbVie
4.  Pfizer Inc.
5. Janssen Biotech
6. GlaxoSmithKline
7. Novartis AG
8. AstraZeneca plc
9. Teva Pharmaceuticals Industries
10. Sanofi S.A

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here